Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gallium-68 NY 104 - Norroy Bioscience

Next Previous
Drug Profile

Gallium-68 NY 104 - Norroy Bioscience

Alternative Names: 68Ga-NY104 PET/CT; 68Ga-NYM-005; 68Ga-NYM005 PET/CT; 68Ga-NY104; Gallium-68 NYM 005 - Norroy Bioscience

Latest Information Update: 06 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Norroy Bioscience
  • Class Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Renal cell carcinoma; Von Hippel-Lindau disease

Most Recent Events

  • 08 Jan 2025 Norroy Bioscience in collaboration with Peking Union Medical College Hospital completes a phase I trial for Renal cell carcinoma (Diagnosis) in China (IV) (NCT06389682)
  • 03 May 2024 Norroy Bioscience intends to file a regulatory application for approval of gallium-68 NY 104 for Renal cell carcinoma (Diagnosis) in the first half of 2025 (Norroy Bioscience pipeline, May 2024)
  • 29 Apr 2024 Norroy Bioscience in collaboration with Peking Union Medical College Hospital initiates a phase I trial for Renal cell carcinoma (Diagnosis) in China (IV) (NCT06389682)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top